LYNPARZA approved in US for HRR gene-mutated metastatic castration-resistant prostate cancer

This article was originally published here

The approval by the US Food and Drug Administration (FDA) was based on results from the Phase III PROfound trial, which were published in the New England Journal

The post LYNPARZA approved in US for HRR gene-mutated metastatic castration-resistant prostate cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply